PI31s

PI31s, also known as PI3K inhibitors, are a class of drugs used to treat various types of cancer. They work by inhibiting the phosphoinositide 3-kinase (PI3K) pathway, which is a crucial signaling pathway involved in cell growth, survival, and proliferation. PI3K inhibitors are particularly effective against cancers that have mutations or amplifications in the PI3K pathway, such as breast, colorectal, and pancreatic cancers.

The most well-known PI3K inhibitor is buparlisib, which was approved by the FDA in 2015 for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Other PI3K inhibitors include alpelisib, idelalisib, and copanlisib, which are used to treat various types of cancer.

PI3K inhibitors are typically administered orally and have a relatively low risk of side effects compared to other cancer treatments. However, they can cause side effects such as diarrhea, fatigue, and increased risk of infections. It is important for patients to discuss the potential benefits and risks of PI3K inhibitors with their healthcare provider before starting treatment.

Research is ongoing to develop new PI3K inhibitors with improved efficacy and fewer side effects. Combining PI3K inhibitors with other targeted therapies or immunotherapies may also enhance their effectiveness in treating cancer.